ABOUT DSV

Deep Science Ventures is creating a future in which both humans and the planet can thrive. We use our unique venture creation process to create, spin-out and invest into science companies, combining available scientific knowledge and founder-type scientists into high-impact ventures. We operate in 4 sectors: Pharmaceuticals, Climate, Agriculture and Computation, tackling the challenges defining those areas by taking a first principles approach and partnering with leading institutions.

WHO SHOULD APPLY

We are looking for an exceptional individual with the following:

ESSENTIAL EXPERIENCE (MUST-HAVE)

• You have translational R&D experience in inflammatory, autoimmune or fibrotic disease.
• 
  
  
  
• Analogous experience in similar diseases/cells/tissues/mechanisms such as fibroblast-targeting in solid tumours is also acceptable.

• You have 15+ years drug development experience in pharma/biotech and/or BD/corporate development experience.
• 
  
  
  
• We are also open to life science VC investors with strong operational drug development experience.

• You have deep commercial & strategic expertise in therapeutic development, demonstrated through successful; (a) VC fundraising (ideally at Series A or Seed), OR, (b) execution of deals (licensing, partnering, collaborations) or transactions (M&A, IPO).
• 
  
  
  
• A strong existing network of investor & pharma BD/CVC relationships is highly preferred.

• Strong track record of building and leading successful teams, ideally with experience integrating in-house operations with outsourced relationships (CROs and/or academic collaborators).

PREFERRED EXPERIENCE (NICE-TO-HAVE)

• Previous CEO experience (in biotech)
• Previous Founder experience (in biotech)
• Technical or clinical development experience in protein therapeutics and/or bispecific antibodies
• Technical or clinical development experience in lung, kidney, liver, or heart fibrosis.
• Deep technical experience in fibrotic disease biology
• Track record of successful non-dilutive (grant) fundraising
• Track record of high quality publications or thought leadership in the field

We are looking for future Founders: entrepreneurially-minded individuals with deep technical and commercial domain expertise, who are eager to solve urgent unmet challenges through venture building. This role offers a unique opportunity to work at the forefront of fibrosis drug development, leading a company solving challenges in immune resolution and myeloid reprogramming to reverse disease.

You will join DSV’s venture creation programme as a Founder-in-Residence and work closely with the DSV and GI team to spin out the new company. During the programme you will refine, improve and complement existing scoping work on:

• Fundraising strategy & pitching
• Clinical strategy & positioning
• Commercial neglect (IP strategy, differentiation, competition)
• Value proposition (market, value capture, techno-economics)
• Optimising company strategy for the most rapid and derisked path to Series A (within 18-24 months from launch)

Preparation for Investment Committee will involve fulfilling any outstanding investment criteria, recruiting advisory and co-founding team members, and parallel fundraising for additional expansion funds.
Assuming success at both respective Investment Committees, you will receive pre-seed investment from DSV and GI, and spinout the company in Q4 2025. You and your co-founders will own a significant stake in the business and continue receiving support post-spinout.